# Inflammation

## Overview

Inflammation is a complex biological response to harmful stimuli such as pathogens, damaged cells, toxic compounds, or irritants. It is a protective response involving immune cells, blood vessels, and molecular mediators, designed to eliminate the initial cause of cell injury, clear out necrotic cells and tissues, and establish repair.

### Purposes of Inflammation
- **Protection**: Remove harmful stimuli and initiate healing
- **Elimination**: Clear pathogens, toxins, and damaged tissue
- **Repair**: Initiate tissue regeneration and wound healing
- **Warning**: Signal tissue damage through pain and other symptoms

## Types of Inflammation

### Acute Inflammation
- **Duration**: Minutes to days
- **Characteristics**: Rapid onset, short duration, innate immune response
- **Cellular infiltrate**: Primarily neutrophils
- **Purpose**: Immediate defense against injury or infection

### Chronic Inflammation
- **Duration**: Weeks to years
- **Characteristics**: Prolonged, involves adaptive immunity
- **Cellular infiltrate**: Macrophages, lymphocytes, plasma cells
- **Purpose**: Persistent response to ongoing stimuli

## Acute Inflammation

### Cardinal Signs
- **Rubor (Redness)**: Vasodilation increases blood flow
- **Calor (Heat)**: Increased blood flow and metabolic activity
- **Dolor (Pain)**: Mediator effects on nerve endings
- **Tumor (Swelling)**: Increased vascular permeability and edema
- **Functio laesa (Loss of function)**: Combined effect of other signs

### Vascular Changes

#### Vasodilation
- **Mechanism**: Smooth muscle relaxation in arterioles
- **Mediators**: Nitric oxide, prostaglandins, histamine
- **Effects**: Increased blood flow, heat, redness
- **Timeline**: Immediate to minutes after injury

#### Increased Vascular Permeability
- **Mechanism**: Endothelial cell contraction, gaps formation
- **Mediators**: Histamine, leukotrienes, complement
- **Effects**: Plasma protein extravasation, edema formation
- **Types**: Immediate transient, immediate sustained, delayed prolonged

#### Blood Flow Changes
- **Initial**: Transient vasoconstriction (seconds)
- **Early**: Vasodilation and increased flow
- **Late**: Slowing of circulation, stasis
- **Consequences**: Facilitates cellular recruitment

### Cellular Events

#### Neutrophil Recruitment
1. **Margination**: Neutrophils move to vessel periphery
2. **Rolling**: Selectin-mediated loose adhesion
3. **Activation**: Chemokine signaling
4. **Firm adhesion**: Integrin-mediated binding
5. **Transmigration**: Movement through vessel wall
6. **Chemotaxis**: Directed migration to injury site

#### Adhesion Molecules
- **Selectins**: P-selectin, E-selectin, L-selectin
- **Integrins**: LFA-1, MAC-1, VLA-4
- **Immunoglobulin superfamily**: ICAM-1, VCAM-1
- **Chemokines**: IL-8, MCP-1, RANTES

### Inflammatory Mediators

#### Vasoactive Mediators
- **Histamine**: Immediate vasodilation and permeability
  - **Source**: Mast cells, basophils, platelets
  - **Effects**: Smooth muscle contraction, increased permeability
  - **Duration**: Short-acting (minutes)

- **Serotonin (5-HT)**: Vasoconstriction and permeability
  - **Source**: Platelets, enterochromaffin cells
  - **Effects**: Similar to histamine
  - **Significance**: Less important in humans than rodents

#### Plasma Protein-Derived Mediators

##### Complement System
- **C3a and C5a (Anaphylatoxins)**:
  - **Effects**: Histamine release, smooth muscle contraction
  - **Chemotaxis**: Neutrophil recruitment
  - **Opsonization**: C3b promotes phagocytosis

- **Membrane Attack Complex (C5b-9)**:
  - **Effects**: Cell lysis, inflammatory mediator release
  - **Regulation**: CD59, other complement regulatory proteins

##### Kinin System
- **Bradykinin**:
  - **Effects**: Vasodilation, increased permeability, pain
  - **Generation**: Kallikrein activation of kininogen
  - **Degradation**: Angiotensin-converting enzyme (ACE)

##### Coagulation and Fibrinolytic Systems
- **Thrombin**: Inflammatory mediator, platelet activation
- **Fibrin**: Hemostasis, inflammatory cell recruitment
- **Plasmin**: Fibrinolysis, complement activation

#### Arachidonic Acid Metabolites

##### Prostaglandins
- **PGE2**: Vasodilation, fever, pain sensitization
- **PGI2 (Prostacyclin)**: Vasodilation, platelet inhibition
- **PGD2**: Bronchoconstriction, neutrophil chemotaxis
- **PGF2α**: Vasoconstriction, bronchoconstriction

##### Leukotrienes
- **LTB4**: Potent neutrophil chemoattractant
- **LTC4, LTD4, LTE4**: Vasoconstriction, bronchoconstriction, increased permeability
- **Clinical significance**: Asthma, allergic responses

##### Lipoxins
- **LXA4, LXB4**: Pro-resolving mediators
- **Effects**: Neutrophil recruitment inhibition
- **Resolution**: Promote inflammation resolution

#### Cytokines
- **TNF-α**: Endothelial activation, systemic effects
- **IL-1β**: Fever, acute phase response
- **IL-6**: Acute phase proteins, fever
- **Chemokines**: Directed cell migration

#### Nitric Oxide
- **Synthesis**: Endothelial NOS, inducible NOS
- **Effects**: Vasodilation, platelet inhibition
- **Dual role**: Protective and potentially harmful

### Cellular Components

#### Neutrophils
- **First responders**: Arrive within hours
- **Functions**: Phagocytosis, degranulation, NET formation
- **Lifespan**: Short (6-24 hours in tissues)
- **Clearance**: Apoptosis and macrophage phagocytosis

#### Macrophages
- **Timing**: Hours to days after injury
- **Origin**: Blood monocytes, tissue-resident macrophages
- **Functions**: Phagocytosis, antigen presentation, repair
- **Phenotypes**: M1 (pro-inflammatory) vs M2 (anti-inflammatory)

#### Mast Cells
- **Location**: Tissue-resident, especially at interfaces
- **Activation**: IgE, complement, direct stimuli
- **Mediators**: Histamine, heparin, TNF-α, leukotrienes
- **Role**: Immediate hypersensitivity, helminth defense

## Chronic Inflammation

### Characteristics
- **Duration**: Prolonged (weeks to years)
- **Cellular infiltrate**: Mononuclear cells
- **Tissue changes**: Fibrosis, angiogenesis
- **Causes**: Persistent infections, autoimmune diseases, foreign materials

### Cellular Components

#### Macrophages
- **Central role**: Tissue destruction and repair
- **Activation states**: Classical (M1) vs alternative (M2)
- **Functions**: Phagocytosis, secretion, antigen presentation
- **Secretory products**: Cytokines, growth factors, enzymes

#### Lymphocytes
- **T cells**: Helper and cytotoxic functions
- **B cells**: Antibody production, antigen presentation
- **NK cells**: Cytotoxicity, cytokine production
- **Adaptive immunity**: Antigen-specific responses

#### Plasma Cells
- **Origin**: Activated B cells
- **Function**: Antibody secretion
- **Morphology**: Eccentric nucleus, abundant cytoplasm
- **Significance**: Chronic antigenic stimulation

#### Eosinophils
- **Associated conditions**: Allergies, parasitic infections
- **Mediators**: Major basic protein, eosinophil peroxidase
- **Functions**: Parasitic defense, tissue damage
- **Regulation**: IL-5, eotaxin

### Granulomatous Inflammation

#### Definition
- **Granuloma**: Collection of activated macrophages (epithelioid cells)
- **Giant cells**: Multinucleated cells formed by macrophage fusion
- **Central role**: Response to persistent antigens

#### Types of Granulomas
- **Caseating**: Central necrosis (tuberculosis)
- **Non-caseating**: No central necrosis (sarcoidosis)
- **Foreign body**: Response to inert materials
- **Immune**: T cell-mediated immune response

#### Giant Cell Types
- **Langhans-type**: Nuclei arranged at periphery (tuberculosis)
- **Foreign body-type**: Random nuclear arrangement
- **Touton**: Foamy cytoplasm (fat necrosis)

## Resolution of Inflammation

### Active Process
- **Not passive**: Requires specific pro-resolving signals
- **Mediators**: Lipoxins, resolvins, protectins, maresins
- **Cellular changes**: Neutrophil apoptosis, macrophage clearance
- **Tissue repair**: Return to homeostasis

### Pro-Resolving Mediators

#### Lipoxins
- **Synthesis**: Lipoxygenase pathways
- **Effects**: Neutrophil recruitment cessation
- **Macrophage function**: Enhanced phagocytosis

#### Resolvins
- **Source**: Omega-3 fatty acids (EPA, DHA)
- **Functions**: Anti-inflammatory, pro-resolving
- **Clinical potential**: Therapeutic targets

### Clearance Mechanisms
- **Apoptosis**: Programmed neutrophil death
- **Efferocytosis**: Macrophage clearance of apoptotic cells
- **Lymphatic drainage**: Removal of fluid and cells
- **Tissue repair**: Restoration of normal architecture

## Systemic Effects of Inflammation

### Acute Phase Response
- **Coordination**: Liver, hypothalamus, bone marrow
- **Mediators**: IL-1, IL-6, TNF-α
- **Changes**: Fever, leukocytosis, acute phase proteins

#### Acute Phase Proteins
- **Positive**: C-reactive protein, serum amyloid A, fibrinogen
- **Negative**: Albumin, transferrin
- **Functions**: Opsonization, complement activation
- **Clinical use**: Inflammatory markers

### Fever
- **Mechanism**: Hypothalamic set-point elevation
- **Mediators**: IL-1, TNF-α, prostaglandins
- **Benefits**: Enhanced immune function
- **Complications**: Hyperthermia, seizures

### Leukocytosis
- **Neutrophilia**: Bacterial infections
- **Lymphocytosis**: Viral infections
- **Eosinophilia**: Allergic reactions, parasites
- **Mechanisms**: Bone marrow mobilization, demargination

## Pathologic Inflammation

### Excessive Inflammation
- **Tissue damage**: Collateral damage from inflammatory response
- **Examples**: Septic shock, acute respiratory distress syndrome
- **Mechanisms**: Uncontrolled mediator release
- **Treatment**: Anti-inflammatory therapy

### Deficient Inflammation
- **Immunodeficiency**: Impaired inflammatory responses
- **Consequences**: Increased infection susceptibility
- **Examples**: Neutropenia, complement deficiencies
- **Treatment**: Supportive care, antimicrobials

### Misdirected Inflammation
- **Autoimmunity**: Self-tissue targeting
- **Examples**: Rheumatoid arthritis, inflammatory bowel disease
- **Mechanisms**: Molecular mimicry, epitope spreading
- **Treatment**: Immunosuppression

## Clinical Applications

### Diagnostic Markers
- **C-reactive protein**: Acute inflammation marker
- **Erythrocyte sedimentation rate**: Nonspecific inflammation
- **Procalcitonin**: Bacterial infection marker
- **Cytokines**: Research and specialized clinical use

### Anti-inflammatory Therapy

#### Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- **Mechanism**: Cyclooxygenase inhibition
- **Effects**: Reduced prostaglandin synthesis
- **Uses**: Pain, fever, inflammation
- **Side effects**: GI ulceration, renal toxicity

#### Corticosteroids
- **Mechanism**: Multiple anti-inflammatory pathways
- **Effects**: Broad immunosuppression
- **Uses**: Severe inflammation, autoimmune diseases
- **Side effects**: Infection risk, metabolic effects

#### Targeted Biologics
- **TNF-α inhibitors**: Rheumatoid arthritis, IBD
- **IL-1 antagonists**: Autoinflammatory diseases
- **Complement inhibitors**: Specific complement-mediated diseases

### Therapeutic Strategies
- **Prevention**: Risk factor modification
- **Early intervention**: Rapid anti-inflammatory treatment
- **Resolution enhancement**: Pro-resolving mediators
- **Precision medicine**: Targeted therapy based on specific pathways

## Key Points

- Inflammation is a protective response designed to eliminate harmful stimuli and initiate healing
- Acute inflammation involves vascular changes and cellular recruitment, primarily neutrophils
- Cardinal signs reflect the underlying vascular and cellular changes
- Inflammatory mediators coordinate the complex inflammatory response
- Chronic inflammation involves mononuclear cells and can lead to tissue damage
- Resolution is an active process requiring specific pro-resolving signals
- Systemic effects include fever, acute phase response, and leukocytosis
- Pathologic inflammation can be excessive, deficient, or misdirected
- Understanding inflammatory mechanisms guides diagnostic and therapeutic approaches
- Anti-inflammatory therapy must balance benefit against infection risk

## References

1. Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Elsevier; 2020.
2. Serhan CN, Chiang N, Dalli J. The resolution of inflammation: from omega-3 fatty acid mediators to therapeutic potential. Nature Reviews Immunology. 2015;15(12):758-770.
3. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140(6):871-882.